Jin Yao is a Senior Principal Scientist at Bristol Myers Squibb, where he plays a pivotal role in advancing the field of immuno-oncology through his expertise in bioinformatics. With over eight years of experience in the pharmaceutical industry, Jin specializes in driving drug discovery and...
Jin Yao is a Senior Principal Scientist at Bristol Myers Squibb, where he plays a pivotal role in advancing the field of immuno-oncology through his expertise in bioinformatics. With over eight years of experience in the pharmaceutical industry, Jin specializes in driving drug discovery and development by harnessing the power of machine learning and statistical modeling. His current focus on translational bioinformatics is instrumental in overseeing the analysis of phase II/III clinical trials targeting gastrointestinal (GI) tract indications, where he leads efforts to derive clinically significant insights from complex multi-modal biomarker data, including genomics, transcriptomics, proteomics, and circulating tumor DNA (ctDNA).
Jin’s work is characterized by a commitment to integrating diverse data types to enhance the understanding of cancer biology and improve patient outcomes. By collaborating closely with translational medicine scientists and clinical development teams, he ensures that the insights generated from his analyses are not only biologically meaningful but also actionable in the clinical setting. His proficiency in advanced computational techniques, including deep learning and statistical modeling, allows him to tackle intricate challenges in drug development, ultimately contributing to the creation of innovative therapies in the biopharmaceutical landscape.
In addition to his technical skills in programming languages such as Matlab and C++, Jin's passion for leveraging computational tools to solve complex problems drives his ongoing contributions to the field. As he continues to push the boundaries of bioinformatics at Bristol Myers Squibb, Jin remains dedicated to enhancing the precision of cancer treatments and improving the lives of patients battling GI cancers.
